Method and System for diterpene production platforms in yeast

Abstract

A method is provided for modifying yeast to express mutant avian farnesyl disphospate synthase and the resulting modified yeast. The yeast advantageously includes additional mutants including but not limited to having ergosterol dependent growth and being erg-. The modified yeast are beneficial for the production of various terpenes including diterpenes.

Claims

1. A genetically modified yeast for the enhanced expression of terpenes produced by a method comprising: combining yeast with a chemical mutagenesis agent to induce mutations in the yeast to generate chemically mutated yeast; selecting chemically mutated yeast which grows in the presence of nystatin, squalestatin and cholesterol, followed by selecting for sterol dependent growth in the presence of squalestatin; subjecting the sterol dependent growth yeast to an erg9 knockout mutation, to thereby produce sterol dependent growth/erg9 knockout mutation yeast cell lines; and inserting an expression vector into the sterol dependent growth/erg9 knockout mutation yeast cells wherein the expression vector expresses a gene for mutant avian farnesyl diphosphate synthase, to thereby produce the genetically modified yeast having a dispensable sterol biosynthetic pathway and genetically modified with a non-naturally occurring prenyltransferase to thereby alter prenyl diphosphate levels and genetically modified to express a terpene synthase directed to diterpene production.

2. The genetically modified yeast of claim 1, wherein the yeast both has an erg9 knockout and has sterol uptake enhancement (SUE) and the yeast can grow in the presence of squalestatin and nystatin and are dependent on exogenous sterol for growth.

3. The genetically modified yeast of claim 1, wherein the yeast is selected from the group consisting of Candida albicans and Saccharomyces cerevisiae.

4. A method for generating terpene producing yeast cell lines, the method comprising: combining yeast with a chemical mutagenesis agent to induce mutations in the yeast to generate chemically mutated yeast; selecting chemically mutated yeast which grows in the presence of nystatin, squalestatin and cholesterol, followed by selecting for sterol dependent growth in the presence of squalestatin; subjecting the sterol dependent growth yeast to an erg9 knockout mutation, to thereby produce sterol dependent growth/erg9 knockout mutation yeast cell lines; and inserting an expression vector into the sterol dependent growth/erg9 knockout mutation yeast cells wherein the expression vector expresses a gene for mutant avian farnesyl diphosphate synthase.

5. The method of claim 4, wherein subjecting the sterol dependent growth yeast to an erg9 knockout mutation comprises inserting a foreign gene sequence into the sterol dependent growth yeast at the location of erg9 to effect gene replacement, thereby generating the erg9 knockout mutation.

6. The method of claim 5, wherein the foreign gene sequence confers chemical resistance to a selected chemical thereby allowing the sterol dependent growth/erg9 knockout mutation yeast to grow in the presence of the chemical.

7. The method of claim 4, wherein the yeast is selected from the group consisting of Candida albicans and Saccharomyces cerevisiae.

8. The genetically modified yeast of claim 1, wherein the terpene synthase is kaurene synthase.

9. The genetically modified yeast of claim 1, wherein the prenyltransferase and the terpene synthase are targeted to the cytoplasm of the genetically modified yeast.

10. The generally modified yeast of claim 1, wherein the dispensable sterol biosynthetic pathway comprises a functional mevalonate pathway not coupled to sterol metabolism.

11. The genetically modified yeast of claim 1, wherein the non-naturally occurring prenyltransferase catalyzes the conversion of dimethylallyl pyrophosphate (DMAPP) and isopentenyl diphosphate (IPP) to yield GGPP.

12. The genetically modified yeast of claim 11, wherein the terpene synthase, expressed for diterpene production by genetic modification, is a heterologous diterpene synthase that converts available geranylgeranyl diphosphate (GGPP) to the production of diterpenes.

13. The genetically modified yeast of claim 1, wherein the terpene synthase, expressed for diterpene production by genetic modification, is a heterologous diterpene synthase that converts available geranylgeranyl diphosphate (GGPP) to the production of diterpenes.

14. The genetically modified yeast of claim 1, wherein subjecting the sterol dependent growth yeast to an erg9 knockout mutation comprises inserting a foreign gene sequence into the sterol dependent growth yeast at the location of erg9 to effect gene replacement, thereby generating the erg9 knockout mutation.

15. The genetically modified yeast of claim 14, wherein the foreign gene sequence confers chemical resistance to a selected chemical thereby allowing the sterol dependent growth/erg9 knockout mutation yeast to grow in the presence of the chemical.

16. The genetically modified yeast of claim 1, wherein the sterol is ergosterol.

Description

BRIEF DESCRIPTION OF THE FIGURES

(1) FIG. 1 shows biosynthesis of terpenes from natural sources, often in mixtures, produced by wild type yeast.

(2) FIG. 2 is schematic outline of two terpene biosynthetic pathways that operate in plants (the MVA and MEP pathways), their intracellular locations, and examples of the chemical compounds derived from each.

(3) FIG. 3 illustrates mevalonate pathway in erogsterol biosynthesis in yeast (S. cerevisiae).

(4) FIG. 4 is a schematic representing compounds of various terpenoid classes and prenyl diphosphates derived.

(5) FIG. 5 is a schematic showing one strategy for developing a yeast line suitable for engineering diterpene chemicals in accordance with the present invention.

(6) FIG. 6 is a graph showing a comparison of terpene chemical profiles in yeast over-expressing the abietadiene synthase (ABS) gene versus control yeast not harboring the ABS gene.

(7) FIG. 7 is a graph showing a comparison of terpene chemical profiles from yeast co-expressing an alternative GGPP synthase (mFPS F112A) with abietadiene synthase versus only over-expressing the abietadiene synthase.

(8) FIG. 8 comprises two graphs showing co-expression of the mFPS gene with different diterpene synthase genes enhances diterpene accumulation.

(9) FIG. 9 illustrates a construct design for testing the importance of specific gene promoters for diterpene (kaurene) production in yeast.

(10) FIG. 10 comprises four graphs showing kaurene and farnesol (FOH) accumulation in yeast engineered for expression of the kaurene synthase and mutant avian FPP synthase driven by different gene promoters.

(11) FIG. 11 shows a comparison of vector configuration effects on abietadine production in ZX 2-2 yeast line.

(12) FIG. 12 is a chart showing kaurene, farnesol (FOH) and geranylgeraniol accumulation in yeast engineered for expression of kaurene synthase and mutant avian FPP synthase driven by different gene promoter combinations on a single gene expression vector.

(13) FIG. 13 comprises two charts show culture medium and temperature influences on abietadiene accumulation.

(14) FIG. 14 shows expression constructs designed for producing diterpene acids in yeast in accordance with the present invention.

(15) FIG. 15 is a chart showing culture medium and temperature influence kaurenoic acid accumulation in accordance with the present invention.

DETAILED DESCRIPTION

(16) The present method and modified yeast will now be described with reference to the figures and exemplary experiments, examples and methods. The figures, experiments and examples are merely to provide a more thorough understanding of the present method and modified yeast. However, other methods and generated yeast can be envisioned consistent with the scope and spirit of this disclosure.

(17) FIG. 5 outlines one approach used to generate yeast lines that provides for robust biosynthesis of precursors that can be utilized for the production of many different classes of terpenes. The schematic diagram in FIG. 5 shows an overall approach used for generating a yeast cell line that have a dispensable sterol biosynthetic pathway (FIG. 5, upper panel A), which provide opportunities for diverting intermediaries (DMAPP, IPP and FPP) from the mevalonate (MVA) pathway for the biosynthesis of diterpene compounds (FIG. 5, lower panel B).

(18) The strategy takes advantage of the native mevalonate (MVA) pathway that operates normally in yeast for the biosynthesis of ergosterol, the dominant sterol found in yeast. Ergosterol is the main product of the yeast mevalonate pathway, is an important membrane component, and is essential for yeast growth. If the ergosterol biosynthetic pathway is blocked or inhibited, yeast die. In fact, this is the basis for many pharmacological drugs to control fungal infections in man (Maertens, 2004) and agricultural chemicals to control fungal infection in plants (Casida, 2009). To further complicate matters, wild type yeast can take up exogenously supplied sterol from their environment only under anaerobic conditions.

(19) In order to be able to efficiently channel terpene biosynthetic intermediates from the ergosterol biosynthetic pathway (FIG. 5, panel A), a SUE (sterol uptake enhancement) mutation supporting the aerobic uptake and utilization of exogenous sterol was first created (Bourot and Karst, 1995; Shianna et al., 2001). A SUE mutation is thus a yeast line that can meet all its sterol needs by an exogenous source of sterol, and therefore making the endogenous ergosterol biosynthetic pathway dispensable (Bourot and Karst). The Bourot and Karst SUE mutation was then complemented by the introduction of a knockout mutation in the ERGS gene (squalene synthase) (Zhang et al., 1993), resulting in a yeast line where the MVA pathway was still operational up to the biosynthesis of FPP and hence, intermediates in the pathway (DMAPP, IPP and FPP) could be diverted to the biosynthesis of other non-essential terpene components.

(20) This technique diverts isoprenoid pathway intermediates to the biosynthesis of diterpenes, to provide high yielding conditions for the production of diterpene hydrocarbons and decorating the diterpene scaffolds to generate additional high-valued chemical entities.

(21) Steps in the Development of High Level Diterpene Accumulation in Yeast

(22) I. Co-Expression of a Mutant Prenyltransferase

(23) Specific efforts and conditions were necessary to generate yeast lines expressing high-level diterpene accumulation. The first was based on the observation that yeast engineered with a diterpene synthase, like abietadiene synthase, ABS (Vogel et al., 1996) tend to accumulate only marginal amounts of the desired diterpene product (FIG. 6). However, when expression of the ABS gene is coupled with the co-expression of a mutant avian farnesyl diphosphate synthase (mtFPS) that exhibits a preferred biosynthesis for geranylgeranyl diphosphate (GGPP) rather than FPP (Tarshis et al., 1996; Fernandez et al., 2000), those yeast lines demonstrated a dramatic accumulation of abietadiene at the expense of farnesol accumulation (FIG. 7). Use of the mtFPS was preferred to other native GGPP synthases because the avian enzyme is particular active as a homodimeric protein and because the enzyme protein is itself relatively small.

(24) Referring to FIG. 6, GC chromatographs of extracts were prepared from yeast engineered for expression of the abietadiene synthase (ABS) gene (upper panel) versus control yeast (those engineered with an empty plasmid DNA, no ABS gene) (lower panel). The yeast lines were grown for approximately 5 days, aliquots of the culture were extracted into hexane, and the hexane extracts then profiled by GC-MS. Cedrene was added to cultures prior to extraction as an external standard to account for sample extraction efficiency (peak 1); farnesol (peak 3) was monitored as an estimation of how much carbon flux to FPP was occurring in the yeast cells; and abietadiene (peak 5) was monitored as a measure of how much isoprenoid intermediates (IPP, DMAPP and FPP) were being diverted to diterpene biosynthesis.

(25) FIG. 7 provides data from GC chromatograms of yeast co-expressing the abietadiene synthase (ABS) and a mutant avian farnesyl diphosphate synthase (mtFPS) (upper panel) versus a yeast line only expressing the ABS gene (lower panel). The yeast lines were grown for approximately 5 days, aliquots of the culture were extracted into hexane, and the hexane extracts then profiled by GC-MS. Cedrene was added to cultures prior to extraction as an external standard to account for sample extraction efficiency (peak 1); farnesol (peak 2) was monitored as an estimation of how much carbon flux to FPP was occurring in the yeast cells, thus escaping channeling to diterpene biosynthesis; and abietadiene (peak 3) was monitored as a measure of how much isoprenoid intermediates (IPP, DMAPP and FPP) were being diverted to specialized diterpene biosynthesis.

(26) FIG. 8 comprises graphs for assessing if the co-expression of the mtFPS gene with different diterpene synthases genes enhances diterpene accumulation. In the upper panel of FIG. 8, yeast engineered for expression of the ABS gene or ABS gene plus mtFPS gene were grown under standard conditions and aliquots of the cultures were monitored daily for growth (OD600 nm) and abietadiene accumulation (GC-MS determination). In the lower panel of FIG. 8, yeast were engineered for expression of a second diterpene synthase gene, kaurene synthase, plus and minus co-expression of the mtFPS gene. Cultures were monitored daily for growth (OD600 nm) and kaurene accumulation (GC-MS).

(27) The benefit of co-expressing the mutant FPS gene with other diterpene synthases for the improved yield of diterpene hydrocarbons was examined with other diterpene synthase genes as well. In FIG. 8, co-expression of the mtFPS gene along with a codon optimized fungal kaurene synthase gene (Toyomasu et al., 2000) dramatically improved kaurene accumulation (lower panel) as observed for abietadiene biosynthesis (upper panel). Equally important to note, the enhanced diterpene accumulation due to the co-expression of the mtFPS did not impose any obvious penalty in cell biomass accumulation (OD600 nm). Cell culture growth was, in fact, improved from 20 to 40% when the diterpene synthase genes were co-expressed with the mutant prenyltransferase.

(28) II. Identification of Gene Expression Promoters and Vector Configurations to Enhance Diterpene Accumulation

(29) The co-expression of the mutant FPS and diterpene synthases provides evidence that the expression level of each gene relative to one another (the stoichiometric relationship) might be an important for optimized diterpene production

(30) FIG. 9 is a schematic showing a construct design for testing the importance of specific gene promoters for diterpene (kaurene) production in yeast. A variety of promoter elements were inserted independently upfront of the mtFPS gene and the fungal kaurene synthase gene followed by the yeast being transformed with all possible combinations of each construct. The different transgenic yeast lines would then evaluate for kaurene production levels.

(31) A variety of gene promoter combinations were evaluated for determining the regulation level of target enzymes in the yeast cells as shown in the strategy outline in FIG. 9.

(32) As shown in FIG. 9, the promoter elements included the actin (act) promoter (Mateus and Avery, 2000), a copper inducible (cup) promoter (Tohoyama et al., 2001), glyceraldehyde phosphate dehydrogenase (gpd) promoter (Bitter and Egan, 1984), transcription elongation factor (tef) promoter (Mumberg et al., 1995), and the alcohol dehydrogenase (adh) promoter, which we previous described using for heterologous expression in yeast (Takahashi et al., 2007). Yeast strain ZX 2-2 was co-transformed with the various two plasmid construct combinations, then individual transformant lines were monitored for kaurene and farnesol accumulation (FIG. 10). While we were obviously screened these lines for the promoter combination giving the highest level of diterpene production, an equal important parameter was the farnesol levels. If a yeast line was efficiently diverting the earlier isoprenoid precursors to diterpene, their farnesol levels would be expected to be equally low. By these criteria, having the GPD promoter direct expression of both the mutant prenyltransferase and the kaurene synthase genes yielded the highest level of kaurene with the greatest efficiency.

(33) The data in the graphs of FIG. 10 were from yeast transformed with the various plasmids noted in FIG. 9, selected for prototrophic growth without leucine or histidene added to the culture media, then grown for 10 days before extracting and chemically profiling aliquots of the cultures by GC-MS. For the line harboring the CUP promoter construct, the cultures were grown for 2 days, then 1 mM copper sulfate was added to the growth media.

(34) The results of FIG. 10 demonstrated that the absolute level of gene expression and stoichiometry of the encoded enzymes influenced overall diterpene production. Next the prenyltransferase and diterpene synthase genes were assembled in separate plasmid vectors or into a single vector. In this way, we were evaluating whether variation in diterpene accumulation could be associated with possible variation in gene copy number as reflected by possible variation in plasmid copy number, or whether a one-to-one stoichiometry of prenyltransferase and diterpene synthase genes on a single plasmid vector were preferable. In the first examination of these possibilities, the constructs relied on the GPD promoter to drive expression of the prenyltransferase and diterpene synthase genes. The constructs were then introduced into yeast and multiple, independent transformants selected for monitoring diterpene (abietadiene) production and farnesol accumulation (FIG. 11). Farnesol accumulation was monitored as a measure of how much carbon was not efficiently being converted to diterpene. Surprisingly, those transgenic lines with the multiple plasmid constructs exhibited relatively minor variation in the level of diterpene and farnesol accumulated, while the lines transformed with the single vector harboring both the prenyltransferase and diterpene synthase genes showed more than 50% variation in the absolute levels of farnesol and abietadiene. Nonetheless, independent transgenic lines containing the targeted genes on a single plasmid vector also demonstrated greater than 30% more abietadiene and farnesol than when the transgenes were introduced on separate plasmid vectors.

(35) FIG. 11 provides data from test showing how the molecular configuration of the mutant prenyltransferase (mtFPS, geranylgeranyl diphosphate synthase) relative to the diterpene synthase (ABS, abietadiene synthase) might influence diterpene production. The indicated plasmid vectors were transformed into yeast ZX 2-2 and 4 independent transgenic lines grown for 10 days prior to extracting and chemically profiling the extracts by GC-MS for abietadiene and farnesol (FOH) accumulation.

(36) The most optimal vector design suggested by the experimental work up to this point suggest that having both the prenyltransferase and diterpene synthase genes on one plasmid vector and having expression of both genes driven by the GPD promoter was the preferred structural organization. This was confirmed in another experiment where the GPD promoter elements within the single plasmid construct were substituted with the ACT, ADH and TEF promoter elements and the transgenic lines examined for farnesol and kaurene accumulation (FIG. 12). Once again, the combination of the dual combination of the GPD promoters proved superior to any other promoter combination with respect to kaurene yield and efficiency, as noted by the limited about of farnesol accumulating.

(37) The graph of FIG. 12 provides data from evaluating the efficiency of the ACT, ADH, TEF or GPD promoters to direct expression of both the mutant prenyltransferase and kaurene synthase genes on a single plasmid vector for diterpene production. Yeast line ZX 2-2 was transformed with the indicated plasmid vector and a resulting transformant line chemically profiled by GC-MS after 10 days of growth.

(38) III. Optimization of Culture Conditions to Enhance Diterpene Accumulation

(39) During the evaluation of genes and genetic elements for enhancing diterpene accumulation, variation in diterpene yields with the culture conditions were observed upon examination of these parameters more systematically, it was discovered that for each diterpene target, specific culture conditions could dramatically influence overall diterpene accumulation. In FIG. 13, the accumulation of abietadiene, farnesol and geranylgeraniol by the same yeast line over-expressing the mutant prenyltransferase and abietadiene synthase genes grown under 4 conditions (2 temperatures and 2 media) was examined. Not unexpectedly, when grown in nutrient rich media (YPDE), the yeast grew approximately 2-fold greater than when cultured in selection media (SCE) for 10 days. However, growth of the cultures at 23 C. versus 30 C. had relatively little influence over this 10-day period in terms of overall biomass accumulation. However, a dramatic effect on abietadiene accumulation was noted when the cultures were grown at 23 C. in selection media. Abietadiene accumulation was 2-fold greater under these conditions than when grown at the higher temperature or in the nutrient rich media. The latter observation might be explained by the loss of the recombinant expression plasmid from the yeast grown in the absence of selection pressure provided by the selection media. In contrast, kaurene accumulation by yeast co-expressing the fungal kaurene synthase and mutant prenyltransferase also under the control of GPD promoters was highest in yeast grown in nutrient rich media rather than selection media, even if the cultures were grown for 10 or more days. Cooler culture temperatures appear to improve diterpene accumulation regardless of the diterpene synthase gene used.

(40) FIG. 13 provides data correlating culture media and temperature influence diterpene accumulation. Yeast strain ZX178-08 co-expressing ABS and mtFPS under the direction of the GPD promoter was grown in nutrient rich media (YPDE) or selection media (SCE) at 23 C. or 30 C. for 10 days. Culture growth was then measure at OD600 nm and terpene accumulation was determined by GC-MS.

(41) IV. Decorating Diterpene Hydrocarbon Scaffolds

(42) Having achieved the production of diterpene hydrocarbon production in yeast, more highly modified forms of diterpenes and especially those molecules that might have industrial, agricultural or medicinal applications were sought. For this purpose, we have utilized a 3 plasmid construct design (FIG. 14). Plasmids 1 and 2 are those described above and whose expression in yeast yields robust levels of diterpenes such as kaurene. The third plasmid construct was similarly designed to constructs 1 and 2, but contained a gene encoding for kaurene oxidase, a fungal P450 enzyme (Tudzynski et al., 2001) requiring reducing equivalents from a cytochrome P450 reductase (CPR) (Takahashi et al., 2007) for activity.

(43) These three vector constructs were transformed into yeast line 2-2 and a confirmed transformant evaluated for diterpene production at 23 C. and 30 C. in nutrient rich media and selection media as described before (FIG. 15). The yeast were grown for 10 days before the accumulation of kaurene and its specific oxidation products kaurenal and kaurenoic acid were measured by GC-MS. Consistent with the earlier observations for kaurene production only, maximal production of approximately 200 mg/I of kaurenoic acid was determined for the culture grown in nutrient rich media at the reduced temperature. This diterpene productivity was about 2-fold greater than the next best conditions, which was the same lower temperature with selection growth media.

(44) FIG. 14 is a schematic showing a construct design for producing diterpene acids in yeast in accordance with the present invention. The mutant prenyltransferase (mtFPS) and kaurene synthase (FKS) constructs were described above and the new construct consisting of a gene encoding for a fungal P450 enzyme catalyzing the oxidation of kaurene to it acidic form (kaurene oxidase, GFKO), plus a cytochrome P450 reductase (CPR) that provides reducing equivalents to the kaurene oxidase. Expression of these genes, like the prenyltransferase and kaurene synthase genes, is controlled by the GPD promoter.

(45) FIG. 15 shows kaurenoic acid production in yeast is media and temperature sensitive. Yeast strain 2-2 was transformed with the 3 plasmid constructs shown in FIG. 14 and a single confirmed transformant grown under the conditions noted. The diterpene profile was determined after 10 days of growth by GC-MS analysis.

(46) The following experiments, methods and procedures provide additional background with regard to the method for producing diterpene platforms in yeast and the resulting yeast produced. In addition, method for producing various knockout mutations in yeast are described in co-pending U.S. Patent Application Serial No.: 14/092,496, herein incorporated by reference.

(47) The following disclosure provides and demonstrates utility of the yeast lines produced in accordance with the present disclosure for diterpene production via a bioreactor scale-up procedure.

Materials and Methods

(48) Chemical and Media Preparations

(49) All chemical reagents were obtained from Sigma-Aldrich (St. Louis, Mo.), BD Bioscience (Franklin Lakes, N.J.), or Fisher Scientific (Chicago, Ill.), while reagents for molecular manipulations were from Stratagene (San Diego, Calif.), Takara (Shiga, Japan), Invitrogen (San Diego, Calif.), and New England Biolab (Ipswich, Mass.).

(50) Bacteria and yeast were grown using standard culture practices. YPD media for growing yeast without selection consisted of 1% Bactoyeast extract, 2% Bacto-peptone, and 2% glucose (or 0.5% glucose for select experiments). YPDE media was YPD media supplemented with ergosterol (40 mg/L) for ergosterol dependent lines. Minimal media, SCE (pH 5.3), contained 0.67% Bacto-yeast nitrogen base (without amino acids), 2% dextrose, 0.6% succinic acid, 0.14% Sigma yeast dropout solution (-his,-leu,-ura,-trp), uracil (300 mg/L), L-tryptophan (150 mg/L), L-histidine (250 mg/L), L-methionine (200 mg/L), L-leucine (lg/L) and 40 mg/L ergosterol. Cholesterol and ergostrol stocks were 10 mg/mL in 50% Triton X-100, 50% ethanol and kept at 20 C. Selection media was prepared similarly except without supplementing the media with the indicated reagent based on the yeast auxotrophic makers. All solid media plates were prepared with 2% Bacto-Agar.

(51) Yeast Strains

(52) The ZX yeast lines used in these studies were disclosed previously. Essentially, these strains were selected for their ability to utilize exogenous sterol sources under aerobic conditions and were engineered with a knockout mutation in their squalene synthase (ERGS) gene such that the basic mevalonate biosynthetic pathway is operative up to FPP biosynthesis. In some cases, similarly constructed yeast strain CALI7 was utilized (Takahashi et al., 2007).

(53) Yeast Transformation and Culture Performance

(54) Yeast strains were transformed with the respective vector constructs using the FROZEN-EZ Yeast Transformation II Kit (Zymo Research, Orange, Calif.) according to the manufacturer's recommendations. About 1 pg of plasmid DNA was used per transformation, followed by selection on agar plates of SCE medium lacking specified amino acids for the auxotrophic markers (selection media) or YPDE (rich media) at 30 C. Variable numbers of independent colonies were subsequently picked and used to start 3 ml cultures in minimal media to characterize their terpene production capacities. Aliquots of these cultures were analyzed for terpene production after 3-6 days of incubation at 30 C. with shaking by GC-MS. Cultures exhibiting the highest terpene production levels were chosen for further studies and archived as glycerol stocks at 80 C. Selected lines were characterized for cell growth and terpene production using 30 mL shake flask cultures. Starter cultures grown to saturation in minimal media were inoculated into 30 ml SCE or YPDE media and 1 mL aliquots withdrawn at indicated intervals for up to 15 days. Cell growth was monitored as the change in optical density at 600 nm, using appropriate dilutions for cultures at later stages of growth. Terpene production was determined by GC-MS similar to the initial screening method.

(55) GC-MS Detection and Quantification of Terpenes

(56) To determine terpene accumulation levels, aliquots of cultures grown for 3 to 12 days were extracted with hexane and aliquots evaluated by GC-MS. In general, to 1 volume of culture, 1 volume of acetone was added and mixed vigorously for 3 to 5 min to lyse the cells. The sample was then allowed to incubate at room temperature for 10 min before adding 1 volume of hexane containing a known amount of cedrene external standard. The mixture was again mixed vigorously, then centrifuged in a clinical centrifuge for 5 min at maximum speed. The upper organic layer was collected and when necessary, concentrated under a N2 stream to 1/10 the original volume. An aliquot of the organic phase (1 pl) was then analyzed by GC-MS with a Varian CP-3800 GC coupled to a Varian Saturn 2200 MS/MS (Varian Medical Systems) using a Supelco SLB-5 ms fused silica capillary column (30 m0.25 mm0.25 pm film thickness, Supelco). The initial oven temperature was set at 70 C. for 1 min, ramped to 200 C. at 8 C./min, and then ramped to 300 C. at 20 C./min and held for 5 min more. Farnesol and diterpene levels were calculated relative to the cedrene external standard.

(57) Expression Vector Construction

(58) The yeast GPD promoter (Pgpd) was amplified from the PYM-N14 plasmid described by Janke et al. (Janke et al., 2004) using the primers GPD-BamHIF and GPD-NotIR primers and inserted into the pESC-His vector digested with BamH1 and Notl to replace the original GAL1/10 promoters. The resulting plasmid was named pESC-His-gpd. The other promoter elements were obtained similarly.

(59) It will be understood that various details of the presently disclosed subject matter can be changed without departing from the scope of the subject matter disclosed herein. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.

REFERENCES

(60) Numerous references have been cited throughout this disclosure including the following. All are incorporated by reference. 1. Anderson M, Che P, Song J, Nikolau B, Wurtele E, 1998. 3-Methylcrotonyl-coenzyme A carboxylase is a component of the mitochondrial leucine catabolic pathway in plants. Plant physiology 118, 1127-38. 2. Anterola A, Shanle E, Perroud P-F, Quatrano R (2009) Production of taxa-4(5),11(12)-diene by transgenic Physcomitrella patens. Transgenic Research 18: 655-660 3. Asadollahi M A, Maury J, Schalk M, Clark A, Nielsen J, 2010. Enhancement of Farnesyl Diphosphate Pool as Direct Precursor of Sesquiterpenes Through Metabolic Engineering of the Mevalonate Pathway in Saccharomyces cerevisiae. Biotechnology and bioengineering 106, 86-96. 4. Barkovich R, Liao J C, 2001. Metabolic engineering of isoprenoids. Metabolic engineering 3, 27-39. 5. Bhilwade H N, Tatewaki N, Nishida H, Konishi T, 2010. Squalene as Novel Food Factor. Current Pharmaceutical Biotechnology 11, 875-80. 6. Bitter G A, Egan K M (1984) Expression Of Heterologous Genes In Saccharomyces-Cerevisiae From Vectors Utilizing The Glyceraldehyde-3-Phosphate Dehydrogenase Gene Promoter. Gene 32: 263-274 7. Bourot S, Karst F (1995) ISOLATION AND CHARACTERIZATION OF THE SACCHAROMYCES-CEREVISIAE SUT1 GENE INVOLVED IN STEROL UPTAKE. Gene 165: 97-102 8. Bouvier F, Rahier A, Camara B, 2005. Biogenesis, molecular regulation and function of plant isoprenoids. Progress in lipid research 44, 357-429. 9. Buchanan B, Gruissem W, Jones R, 2002. Biochemistry & Molecular Biology of Plants. John Wiley & Sons. 10. Burke Y D, Stark M J, Roach S L, Sen S E, Crowell P L, 1997. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 32, 151-6. 11. Cardenas C, Quesada A R, Medina M A (2011) Anti-Angiogenic and Anti-Inflammatory Properties of Kahweol, a Coffee Diterpene. Plos One 6 12. Carrau F M, Medina K, Boido E, et al., 2005. De novo synthesis of monoterpenes by Saccharomyces cerevisiae wine yeasts. FEMS microbiology letters 243, 107-15. 13. Casida J E (2009) Pest Toxicology: The Primary Mechanisms of Pesticide Action. Chemical Research in Toxicology 22: 609-619 14. DeJong J M, Liu Y L, Bollon A P, Long R M, Jennewein S, Williams D, Croteau R B (2006) Genetic engineering of Taxol biosynthetic genes in Saccharomyces cerevisiae. Biotechnology and Bioengineering 93: 212-224 15. Engels B, Dahm P, Jennewein S (2008) Metabolic engineering of taxadiene biosynthesis in yeast as a first step towards Taxol (Paclitaxel) production. Metabolic Engineering 10: 201-206 16. Farhi M, Marhevka E, Masci T, et al., 2011. Harnessing yeast subcellular compartments for the production of plant terpenoids. Metabolic engineering 13, 474-81. 17. Fernandez S M S, Kellogg B A, Poulter C D (2000) Farnesyl diphosphate synthase. Altering the catalytic site to select for geranyl diphosphate activity. Biochemistry 39: 15316-15321 18. Fischer M J C, Meyer S, Claudel P, Bergdoll M, Karst F, 2011. Metabolic Engineering of Monoterpene Synthesis in Yeast. Biotechnology and Bioengineering 108, 1883-92. 19. Grassmann J (2005) Terpenoids as plant antioxidants. In G Litwack, ed, Plant Hormones, Vol 72, pp 505-535 20. Havaux M, DaIIOsto L, Cuine S, Giuliano G, Bassi R (2004) The effect of zeaxanthin as the only xanthophyll on the structure and function of the photosynthetic apparatus in Arabidopsis thaliana. Journal of Biological Chemistry 279: 13878-13888 21. Hick A J, Luszniak M C, Pickett J A, 1999. Volatile isoprenoids that control insect behaviour and development. Natural Product Reports 16, 39-54. 22. Huang Z-R, Lin Y-K, Fang J-Y, 2009. Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology. Molecules 14, 540-54. 23. Janke C, Magiera M M, Rathfelder N, Taxis C, Reber S, Maekawa H, Moreno-Borchart A, Doenges G, Schwob E, Schiebel E, Knop M (2004) A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes. Yeast 21: 947-962 24. Kovacs K, Zhang L, Linforth R S T, Whittaker B, Hayes C J, Fray R G (2007) Redirection of carotenoid metabolism for the efficient production of taxadiene taxa-4(5),11(12)-diene in transgenic tomato fruit. Transgenic Research 16: 121-126 25. Maertens J A (2004) History of the development of azole derivatives. Clinical Microbiology and Infection 10: 1-10 26. Maimone T J, Baran P S, 2007. Modern synthetic efforts toward biologically active terpenes. Nature chemical biology 3, 396-407. 27. Martin V J J, Pitera D J, Withers S T, Newman J D, Keasling J D, 2003. Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nature Biotechnology 21, 796-802. 28. Mateus C, Avery S V (2000) Destabilized green fluorescent protein for monitoring dynamic changes in yeast gene expression with flow cytometry. Yeast 16: 1313-1323 29. Maury J, Asadollahi M A, Mller K, Clark A, Nielsen J, 2005. Microbial isoprenoid production: an example of green chemistry through metabolic engineering. Advances in biochemical engineering/biotechnology 100, 19-51. 30. Mumberg D, Muller R, Funk M (1995) Yeast Vectors For The Controlled Expression Of Heterologous Proteins In Different Genetic Backgrounds. Gene 156: 119-122 31. Nicolaou K C, Yang Z, Liu J J, Ueno H, Nantermet P G, Guy R K, Claiborne C F, Renaud J, Couladouros E A, Paulvannan K, Sorensen E J (1994) TOTAL SYNTHESIS OF TAXOL. Nature 367: 630-634 32. Ohnuma S I, Narita K, Nakazawa T, et al., 1996. A role of the amino acid residue located on the fifth position before the first aspartate-rich motif of farnesyl diphosphate synthase on determination of the final product. The Journal of biological chemistry 271, 30748-54. 33. Porto T S, Rangel R, Furtado N, de Carvalho T C, Martins C H G, Veneziani R C S, Da Costa F B, Vinholis A H C, Cunha W R, Heleno V C G, Ambrosio S R (2009) Pimarane-type Diterpenes: Antimicrobial Activity against Oral Pathogens. Molecules 14: 191-199 Roberts S C (2007) Production and engineering of terpenoids in plant cell culture. Nature Chemical Biology 3: 387-395 34. Reddy L H, Couvreur P, 2009. Squalene: A natural triterpene for use in disease management and therapy. Advanced Drug Delivery Reviews 61, 1412-26. 35. Shianna K V, Dotson W D, Tope S, Parks L W (2001) Identification of a UPC2 homolog in Saccharomyces cerevisiae and its involvement in aerobic sterol uptake. Journal of Bacteriology 183: 830-834 36. Takahashi 5, Yeo Y, Greenhagen B T, McMullin T, Song L, Maurina-Brunker J, Rosson R, Noel J P, Chappell J (2007) Metabolic engineering of sesquiterpene metabolism in yeast. Biotechnology and Bioengineering 97: 170-181 37. Tarshis L C, Proteau P J, Kellogg B A, Sacchettini J C, Poulter C D (1996) Regulation of product chain length by isoprenyl diphosphate synthases. Proceedings of the National Academy of Sciences of the United States of America 93: 15018-15023 38. Tohoyama H, Kadota H, Shiraishi E, Inouhe M, Joho M (2001) Induction for the expression of yeast metallothionein gene, CUP1, by cobalt. Microbios 104: 99-104 39. Toyomasu T, Kawaide H, lshizaki A, Shinoda S, Otsuka M, Mitsuhashi W, Sassa T (2000) Cloning of a full-length cDNA encoding ent-kaurene synthase from Gibberella fujikuroi: Functional analysis of a bifunctional diterpene cyclase. Bioscience Biotechnology and Biochemistry 64: 660-664 40. Tu Y, 2011. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Medicine 17, 1217-20. 41. Tudzynski B, Hedden P, Carrera E, Gaskin P (2001) The P450-4 gene of Gibberella fujikuroi encodes ent-kaurene oxidase in the gibberellin biosynthesis pathway. Applied and Environmental Microbiology 67: 3514-3522 42. Vogel B S, Wildung M R, Vogel G, Croteau R (1996) Abietadiene synthase from grand fir (Abies grandis)cDNA isolation, characterization, and bacterial expression of a bifunctional diterpene cyclase involved in resin acid biosynthesis. Journal of Biological Chemistry 271: 23262-23268 43. Wall M E, Wani M C (1995) PACLITAXELFROM DISCOVERY TO CLINIC. In GICTTOIVDM Georg, ed, Taxane Anticancer Agents: Basic Science and Current Status, Vol 583, pp 18-30 44. Wu S Q, Schalk M, Clark A, Miles R B, Coates R, Chappell J (2006) Redirection of cytosolic or plastidic isoprenoid precursors elevates terpene production in plants. Nature Biotechnology 24: 1441-1447 45. Yamaguchi S (2008) Gibberellin metabolism and its regulation. In Annual Review of Plant Biology, Vol 59, pp 225-251 46. Zhang D L, Jennings S M, Robinson G W, Poulter C D (1993) YEAST SQUALENE SYNTHASEEXPRESSION, PURIFICATION, AND CHARACTERIZATION OF SOLUBLE RECOMBINANT ENZYME. Archives of Biochemistry and Biophysics 304: 133-143 47. Zhou Y J, Gao W, Rong Q, et al., 2012. Modular pathway engineering of diterpenoid synthases and the mevalonic acid pathway for miltiradiene production. Journal of the American Chemical Society 134, 3234-41.